Last reviewed · How we verify
Sodium ST20
At a glance
| Generic name | Sodium ST20 |
|---|---|
| Sponsor | HemaQuest Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon (PHASE2)
- Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand (PHASE2)
- A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium ST20 CI brief — competitive landscape report
- Sodium ST20 updates RSS · CI watch RSS
- HemaQuest Pharmaceuticals Inc. portfolio CI